Pages that link to "Q418819"
Jump to navigation
Jump to search
The following pages link to exemestane (Q418819):
Displaying 50 items.
- breast cancer (Q128581) (← links)
- cytochrome P450 family 19 subfamily A member 1 (Q415287) (← links)
- invasive ductal carcinoma (Q1671685) (← links)
- PGR Expression (Q28444973) (← links)
- Exemestane: a review of its use in postmenopausal women with advanced breast cancer (Q33959115) (← links)
- Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons. (Q36927755) (← links)
- A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (Q44795543) (← links)
- Aromasin (Q47521192) (← links)
- A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] and/or PgR [Progesterone Receptor] Breast Cancer (Q61922249) (← links)
- Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer (Q61932852) (← links)
- Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer (Q61970147) (← links)
- Exemestane in Advanced and Recurrent Endometrial Carcinoma (Q61975791) (← links)
- Exemestane and Cyclophosphamide for Metastatic Breast Cancer (Q61975921) (← links)
- Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (Q61981226) (← links)
- Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (Q62054080) (← links)
- Entinostat Versus Placebo Combined With Endocrine Therapy in Chinese Patients With Advanced Breast Cancer in Chinese Patients With Hormone Receptor-Positive Advanced Breast Cancer (Q62813227) (← links)
- Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer (Q63010681) (← links)
- Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not (Q63319104) (← links)
- Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer (Q63321573) (← links)
- A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr Patients (Q63336444) (← links)
- 1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer (Q63337002) (← links)
- Trial of MK-2206 Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer (Q63340258) (← links)
- MK-2206 Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer (Q63340259) (← links)
- Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer (Q63340359) (← links)
- Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer (Q63340573) (← links)
- A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) (Q63340798) (← links)
- 500mg Fulvestrant Versus Exemestane in MBC (Q63396909) (← links)
- A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (Q63571378) (← links)
- Exemestane-RAD001-Metformin (Q63572603) (← links)
- Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer (Q63572639) (← links)
- Breast Cancer Treatment Based on Organ-like Culture (Q63573270) (← links)
- Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02 (Q63573352) (← links)
- Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02 (Q63573374) (← links)
- The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread (Q63573752) (← links)
- Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer (Q63574281) (← links)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (Q63576345) (← links)
- Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer (Q63578563) (← links)
- Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC (Q63579469) (← links)
- 500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI (Q63598770) (← links)
- Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR / HER2- Locally Advanced or Metastatic Breast Cancer (Q63812248) (← links)
- CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (Q63813211) (← links)
- Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER Breast Cancer (Q86247511) (← links)
- Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer (Q94573541) (← links)
- Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients (Q105789539) (← links)
- metformin / exemestane combination therapy (Q111399003) (← links)
- Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer (Q113887370) (← links)
- Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (Q113887866) (← links)
- A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (Q113890883) (← links)
- A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER ) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer (Q113892423) (← links)
- Analysis of Therapy Sequence in Women With HR , HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. (Q113910039) (← links)